β2-MICROGLOBULIN, A TUMOUR MARKER OF LYMPHOPROLIFERATIVE DISORDERS
- 8 July 1978
- journal article
- other
- Published by Elsevier BV in The Lancet
- Vol. 312 (8080), 108-109
- https://doi.org/10.1016/s0140-6736(78)91428-9
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- CONTRIBUTION OF LEAD IN DRINKING WATER TO BLOOD-LEADThe Lancet, 1977
- DEPENDENCE OF BLOOD-LEAD ON DOMESTIC WATER LEADThe Lancet, 1976
- β2-Microglobulin levels in cancerous and other disease statesClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Effects of Anti-β2 microglobulin antibodies on human lymphocytesCellular Immunology, 1975
- β2-Microglobulin: occurrence in fetal life and malignancyClinica Chimica Acta; International Journal of Clinical Chemistry, 1974
- Multiple Common Properties of Human β 2 -Microglobulin and the Common Portion Fragment Derived from HL-A Antigen MoleculesProceedings of the National Academy of Sciences of the United States of America, 1973
- Serum β2-microglobulin in various disordersClinica Chimica Acta; International Journal of Clinical Chemistry, 1973
- The Serum Levels and Urinary Excretion of β2-Microglobulin in Apparently Healthy SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1972
- Isolation and Properties of a Low Molecular Weight β2-Globulin Occurring in Human Biological FluidsPublished by Elsevier BV ,1968